These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

404 related items for PubMed ID: 17989308

  • 1. A randomized trial comparing continuous subcutaneous insulin infusion of insulin aspart versus insulin lispro in children and adolescents with type 1 diabetes.
    Weinzimer SA, Ternand C, Howard C, Chang CT, Becker DJ, Laffel LM, Insulin Aspart Pediatric Pump Study Group.
    Diabetes Care; 2008 Feb; 31(2):210-5. PubMed ID: 17989308
    [Abstract] [Full Text] [Related]

  • 2. Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: a randomized study in type 1 diabetes.
    Bode B, Weinstein R, Bell D, McGill J, Nadeau D, Raskin P, Davidson J, Henry R, Huang WC, Reinhardt RR.
    Diabetes Care; 2002 Mar; 25(3):439-44. PubMed ID: 11874927
    [Abstract] [Full Text] [Related]

  • 3. Insulin Lispro with Continuous Subcutaneous Insulin Infusion is Safe and Effective in Patients with Type 2 Diabetes: A Randomized Crossover Trial of Insulin Lispro Versus Insulin Aspart.
    Thrasher J, Bhargava A, Rees TM, Wang T, Guzman CB, Glass LC.
    Endocr Pract; 2015 Mar; 21(3):247-57. PubMed ID: 25370322
    [Abstract] [Full Text] [Related]

  • 4. Comparison of a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) in type 1 diabetes: a randomized open parallel multicenter study.
    Bolli GB, Kerr D, Thomas R, Torlone E, Sola-Gazagnes A, Vitacolonna E, Selam JL, Home PD.
    Diabetes Care; 2009 Jul; 32(7):1170-6. PubMed ID: 19389820
    [Abstract] [Full Text] [Related]

  • 5. Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII.
    Hirsch IB, Bode BW, Garg S, Lane WS, Sussman A, Hu P, Santiago OM, Kolaczynski JW, Insulin Aspart CSII/MDI Comparison Study Group.
    Diabetes Care; 2005 Mar; 28(3):533-8. PubMed ID: 15735183
    [Abstract] [Full Text] [Related]

  • 6. Insulin glulisine compared to insulin aspart and to insulin lispro administered by continuous subcutaneous insulin infusion in patients with type 1 diabetes: a randomized controlled trial.
    van Bon AC, Bode BW, Sert-Langeron C, DeVries JH, Charpentier G.
    Diabetes Technol Ther; 2011 Jun; 13(6):607-14. PubMed ID: 21457066
    [Abstract] [Full Text] [Related]

  • 7. Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens using insulin lispro in type 1 diabetic patients on intensified treatment: a randomized study. The Study Group for the Development of Pump Therapy in Diabetes.
    Hanaire-Broutin H, Melki V, Bessières-Lacombe S, Tauber JP.
    Diabetes Care; 2000 Sep; 23(9):1232-5. PubMed ID: 10977011
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of treatment satisfaction associated with the use of insulin aspart in continuous subcutaneous insulin infusion.
    Wittlin SD, Marcus AO, Weng CS, Howard CP, Schorr AB, CONTROL Study Group.
    Diabetes Technol Ther; 2008 Feb; 10(1):1-10. PubMed ID: 18275357
    [Abstract] [Full Text] [Related]

  • 9. Better postprandial glucose stability during continuous subcutaneous infusion with insulin aspart compared with insulin lispro in patients with type 1 diabetes.
    Bartolo PD, Pellicano F, Scaramuzza A, Sardu C, Casetti T, Bosi E, Miselli V, Brandolini S, Fabbri T, Meandri P, Cannatà F.
    Diabetes Technol Ther; 2008 Dec; 10(6):495-8. PubMed ID: 19049379
    [Abstract] [Full Text] [Related]

  • 10. Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Results of a multicenter trial. German Humalog-CSII Study Group.
    Renner R, Pfützner A, Trautmann M, Harzer O, Sauter K, Landgraf R.
    Diabetes Care; 1999 May; 22(5):784-8. PubMed ID: 10332682
    [Abstract] [Full Text] [Related]

  • 11. Continuous subcutaneous infusion of insulin lispro in children and adolescents with type 1 diabetes mellitus.
    Kaiserman K, Rodriguez H, Stephenson A, Wolka L, Fahrbach JL.
    Endocr Pract; 2012 May; 18(3):418-24. PubMed ID: 22297055
    [Abstract] [Full Text] [Related]

  • 12. A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine.
    Doyle EA, Weinzimer SA, Steffen AT, Ahern JA, Vincent M, Tamborlane WV.
    Diabetes Care; 2004 Jul; 27(7):1554-8. PubMed ID: 15220227
    [Abstract] [Full Text] [Related]

  • 13. Switch to multiple daily injections with insulin glargine and insulin lispro from continuous subcutaneous insulin infusion with insulin lispro: a randomized, open-label study using a continuous glucose monitoring system.
    Bode BW, Steed RD, Schleusener DS, Strange P.
    Endocr Pract; 2005 Jul; 11(3):157-64. PubMed ID: 16239201
    [Abstract] [Full Text] [Related]

  • 14. Effect of continuous subcutaneous insulin infusion with lispro on hepatic responsiveness to glucagon in type 1 diabetes.
    Launay B, Zinman B, Tildesley HD, Strack T, Chiasson JL.
    Diabetes Care; 1998 Oct; 21(10):1627-31. PubMed ID: 9773721
    [Abstract] [Full Text] [Related]

  • 15. A comparison of the rapid-acting insulin analogue glulisine with lispro and aspart for the pump treatment of patients with type 1 diabetes.
    Bramlage P, Tittel SR, Müther S, Reinhart-Steininger B, Haberland H, Khodaverdi S, Zimny S, Ohlenschläger U, Lanzinger S, Haak T.
    Acta Diabetol; 2022 Nov; 59(11):1453-1460. PubMed ID: 35933650
    [Abstract] [Full Text] [Related]

  • 16. Continuous subcutaneous insulin infusion versus multiple daily injections: the impact of baseline A1c.
    Retnakaran R, Hochman J, DeVries JH, Hanaire-Broutin H, Heine RJ, Melki V, Zinman B.
    Diabetes Care; 2004 Nov; 27(11):2590-6. PubMed ID: 15504991
    [Abstract] [Full Text] [Related]

  • 17. Glycemic control after 6 days of insulin pump reservoir use in type 1 diabetes: results of double-blind and open-label cross-over trials of insulin lispro and insulin aspart.
    Tamborlane WV, Renard E, Wadwa RP, Blevins T, Jacober SJ, Liu R, D'Souza DN, Rees TM.
    J Diabetes; 2015 Mar; 7(2):270-8. PubMed ID: 24734891
    [Abstract] [Full Text] [Related]

  • 18. Comparison between a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) using continuous glucose monitoring in metabolically optimized type 1 diabetes patients: A randomized open-labelled parallel study.
    Ruiz-de-Adana MS, Dominguez-Lopez ME, Gonzalez-Molero I, Machado A, Martin V, Cardona I, de-la-Higuera M, Tapia MJ, Soriguer F, Anarte MT, Rojo-Martínez G.
    Med Clin (Barc); 2016 Mar 18; 146(6):239-46. PubMed ID: 26656958
    [Abstract] [Full Text] [Related]

  • 19. Use of rapid-acting insulin analogues in the treatment of patients with type 1 and type 2 diabetes mellitus: insulin pump therapy versus multiple daily injections.
    Bode BW.
    Clin Ther; 2007 Mar 18; 29 Suppl D():S135-44. PubMed ID: 18191065
    [Abstract] [Full Text] [Related]

  • 20. Special management of insulin lispro in continuous subcutaneous insulin infusion in young diabetic children: a randomized cross-over study.
    Tubiana-Rufi N, Coutant R, Bloch J, Munz-Licha G, Delcroix C, Montaud-Raguideau N, Ducrocq R, Limal JM, Czernichow P.
    Horm Res; 2004 Mar 18; 62(6):265-71. PubMed ID: 15523183
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.